Entasis Therapeutics Holdings Inc. ETTX
2.19 0.00 (+0.00%)
At closeJul 8, 2022, 4:00 PM EDT
2.19 Day range 2.20
52-week range unavailable
- Open
- 2.19
- Previous close
- 2.19
- Day's range
- 2.19 – 2.20
- Analysts
- Hold
- Price target
- 2.00 (-8.7%)
- Earnings date
- Aug 10, 2022
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2022
Expected Aug 10, 2022. Consensus EPS estimate -0.29.
Financials — quick view
ETTX Revenue — quarterly 0
ETTX Net income — quarterly -15.26M
ETTX EPS — quarterly -0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2022 | Jun 1, 2022 | -0.28 | — | — | — |
| Apr 27, 2022 | Mar 1, 2022 | -0.20 | — | — | — |
| Mar 3, 2022 | Dec 1, 2021 | -0.26 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.26 | — | — | — |
| Aug 11, 2021 | Jun 1, 2021 | -0.24 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | -0.34 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 5, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
| Mar 15, 2022 | Alliance Global Partners | down | Buy | Neutral |
| Mar 7, 2022 | Wedbush | down | Outperform | Neutral |
| Mar 3, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 19, 2021 | BMO Capital | main | — | Outperform |
| Oct 18, 2021 | HC Wainwright & Co. | main | — | Buy |
News
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China 
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. 
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. 
Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX 
Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX 
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc. 
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva 
ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX 
ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to Shareholders 
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
Your note
Sign in to keep a note on ETTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERGER HEATHER | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
| GUTCH MICHAEL PH.D. | Chief Financial Officer | Stock Award(Grant) | Jan 17, 2022 | 167,572 |
| HASTINGS DAVID C | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
| KEILEY ELIZABETH M | General Counsel | Stock Award(Grant) | Jan 17, 2022 | 167,572 |
| MAYER HOWARD | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
| MEEK DAVID D | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tpg Group Holdings (sbs) Advisors, Inc. | 2.13% | 1,020,748 | 3.41M | Sep 29, 2021 |
| TPG GP A, LLC | 2.13% | 1,020,748 | 1.91M | Mar 30, 2022 |
| Eventide Asset Management LLC | 1.23% | 590,602 | 1.10M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 1.01% | 483,723 | 904.56K | Mar 30, 2022 |
| Renaissance Technologies, LLC | 0.68% | 323,845 | 605.59K | Mar 30, 2022 |
| Bridgeway Capital Management, Inc. | 0.28% | 132,600 | 247.96K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Gilead Fund | 1.23% | 590,602 | 1.10M | Mar 30, 2022 |
| Vanguard Total Stock Market Index Fund | 0.64% | 304,345 | 569.13K | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 0.36% | 173,140 | 323.77K | Mar 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.28% | 132,600 | 247.96K | Mar 30, 2022 |
| Fidelity Extended Market Index Fund | 0.18% | 86,160 | 187.83K | May 30, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 32,026 | 69.82K | May 30, 2022 |